Lawsuits over the popular heartburn medicine Zantac continue, with recent new claims from Pennsylvania and Florida. Two women have filed lawsuits in U.S. District Court for the Southern District of Florida. That’s where the consolidated multidistrict Zantac litigation is currently pending. The women contend that regular use of Zantac caused colon and pancreatic cancer. They blame the presence of N-nitrosodimethylamine (NDMA), a cancer-causing agent.
The Pennsylvania lawsuit was filed on behalf of the deceased victim’s estate. The complaint alleges that the victim would not have taken Zantac if he had known of the cancer-causing risks. The victim was diagnosed with pancreatic cancer in 2018, and died on August 31, 2019.
Meanwhile, in the Florida complaint, the woman alleges that she took Zantac regularly for over two decades. She took both the 75 mg and 150 mg doses, and began using the drug after undergoing an endoscopy. Her doctor advised her to take Zantac to reduce her stomach acid.
Notably, the woman started using the 150 mg dose when it became available in the United States. She alleges that Zantac advertising convinced her the drug could relieve acid reflux and sour stomach. She was diagnosed with stage IIIC colon cancer in April 2018. As a result, she had to undergo surgery to remove a large portion of her colon. This was followed by chemotherapy treatments every two weeks for a period of over six months.
As with other similar lawsuits, the plaintiffs here are demanding compensatory and punitive damages. Compensatory damages – money to compensate the victim for economic and non-economic losses – are fairly standard in civil cases. Punitive damages are relatively less common. As the name suggests, they are sought to punish a defendant for particularly egregious conduct.
In September 2019, the FDA warned of the presence of NDMA in Zantac and generic versions of the drug (ranitidine). The FDA recommended that manufacturers test their products. Soon afterwards, several drug makers recalled their ranitidine products from the market.
The FDA then conducted its own tests. In April 2020, the agency requested the recall of all ranitidine products. But there’s even worse news for regular users of the drug. Independent studies have shown that the presence of NDMA could increase with time and exposure to high temperatures.
Lawsuits typically allege that the makers of these drugs knew, or should have known, of the health risks. But despite that knowledge, they failed to provide adequate warnings. Some lawsuits even claim the drug makers deliberately concealed evidence to increase their profits.
If you or a loved one have developed cancer or other injuries, see your primary care physician right away. Then, contact an experienced defective drug attorney. Dalimonte Rueb is actively taking Zantac and ranitidine clients. The exact damages you can claim will depend on the individual facts in your case. However, these sorts of lawsuits typically demand such damages as:
- Medical costs for past, present, and future treatments
- Prescription drug medications as part of your treatment
- Lost wages due to time missed from work
- Lost earning capacity due to inability to work at the same level
- Pain and suffering
As the Pennsylvania lawsuit illustrates, there are tragic cases in which the victim dies from their injuries. In situations like this, eligible survivors can pursue a wrongful death lawsuit against the responsible party. Our firm has experience with these cases and can assist your family in seeking justice.
Let Our Experienced Drug Injury Attorneys Work With You Today
No one should have to worry that they or a loved one will suffer because of a drug company’s negligence. But if you or a loved one have been injured by Zantac, you do have legal options. Let the experienced drug defect and drug injury attorneys of Dalimonte Rueb help. Give us a call today to schedule your consultation.